key: cord-0852498-8i2ryrfe
authors: Poh, Xuan Ying; Tan, Chee Wah; Lee, I. Russel; Chavatte, Jean-Marc; Fong, Siew-Wai; Prince, Tessa; Hartley, Catherine; Yeoh, Aileen Ying-Yan; Rao, Suma; Chia, Po Ying; Ong, Sean WX; Lee, Tau Hong; Sadarangani, Sapna P.; Lin, Ray JH; Lim, Clarissa; Teo, Jefanie; Lim, Daniel RX; Chia, Wanni; Hiscox, Julian A.; Ng, Lisa F.P.; Ren, Ee Chee; Lin, Raymond TP; Renia, Laurent; Lye, David Chien; Wang, Lin-Fa; Young, Barnaby E
title: Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A Randomized Clinical Trial
date: 2022-05-11
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac345
sha: 168f3da6133c57726ea775de3a85316db121ca32
doc_id: 852498
cord_uid: 8i2ryrfe

BACKGROUND: Waning antibody levels post-vaccination and the emergence of variants of concern (VOCs) capable of evading protective immunity has raised the need for booster vaccinations. However, which combination of COVID-19 vaccines offers the strongest immune response against Omicron variant is unknown. METHODS: This randomized, subject-blinded, controlled trial assessed the reactogenicity and immunogenicity of different COVID-19 vaccine booster combinations. 100 BNT162b2-vaccinated individuals were enrolled and randomized 1: 1 to either homologous (BNT162b2 + BNT162b2 + BNT162b2; ‘BBB’) or heterologous mRNA booster vaccine (BNT162b2 + BNT162b2 + mRNA-1273; ‘BBM’). Primary endpoint was the level of neutralizing antibodies against SARS-CoV-2 wild-type and VOCs at Day 28. RESULTS: 51 participants were allocated to BBB and 49 to BBM; 50 and 48 respectively were analyzed for safety and immunogenicity outcomes. At Day 28 post-boost, mean SARS-CoV-2 spike antibody titers were lower with BBB (22,382 IU/mL 95% CI, 18,210 to 27,517) vs BBM (29,751 IU/mL 95% CI, 25,281 to 35,011, p = 0.034) as was the median level of neutralizing antibodies: BBB 99.0% (IQR 97.9 to 99.3%) vs BBM 99.3% (IQR 98.8 to 99.5%, p = 0.021). On sub-group analysis, significant differences in mean spike antibody titer and live Omicron neutralization titer was only observed in older adults. Median surrogate neutralizing antibody level against all VOCs was also significantly higher with BBM in older adults, and against Omicron was BBB 72.8% (IQR 54.0 to 84.7%) vs BBM 84.3% (IQR 78.1 to 88.7%, p = 0.0073). Both vaccines were well tolerated. CONCLUSIONS: Heterologous mRNA-1273 booster vaccination induced a stronger neutralizing response against the Omicron variant in older individuals compared with homologous BNT123b2.

have occurred with increasing frequency as a result of waning antibody levels and the 4 emergence of variants of concern (VOCs) such as Omicron which are capable of evading 5 protective immunity. 1,2 All COVID-19 vaccines currently approved by the World Health 6

Organization (WHO) Emergency Use Listing (EUL) were developed with the wild-type SARS-7

CoV-2 strain that emerged in Wuhan in 2019. 3 8

Within a few months from its discovery in November 2021, the Omicron variant supplanted 9

Delta as the dominant strain detected worldwide. 4 Several immunogenicity studies of vaccines have demonstrated that a booster dose is needed to elicit an anti-Omicron neutralizing 11 response. 2,4-6 Vaccine booster combinations tested include homologous mRNA vaccines such 12 as BNT162b2 2,4,6 and mRNA-1273 2 , as well as non-replicating viral vector vaccines 13 AD26.COV2.3 2 and AZD1222 6 . However, whether homologous or heterologous mRNA booster 14 vaccination regimens are better at inducing neutralizing antibodies against Omicron, and 15 whether different age groups respond differently to the various vaccine booster combinations is 16

In this interim analysis of a phase 4 randomized, subject-blinded clinical trial, we studied the 18 immunogenicity of BNT162b2 versus mRNA-1273 booster vaccinations in individuals who had 19 received the second dose of the BNT162b2 vaccine as a primary series at least six months prior 20

to study enrolment. The study is still ongoing and participants who received mRNA-1273 as 21 their primary series will be included in later phases of the study. Primary endpoint was antibody 22 levels against wild-type SARS-CoV-2 and VOCs as measured by a multiplex surrogate virus 23 neutralization test (sVNT) . 24 A C C E P T E D M A N U S C R I P T

The primary objective for this clinical trial is to determine whether a heterologous mRNA-1273 4 COVID-19 vaccine booster leads to non-inferior humoral immunity against wild-type SARS-CoV-5 2 and/or VOCs at day 28 compared with homologous BTN162b2. This was assessed by a 6 surrogate virus neutralization test (sVNT) that detects total immuno-dominant neutralizing 7 antibodies targeting the viral spike protein receptor-binding domain in an isotype-and species-8 independent manner. 9

Interim analyses were performed for Data Safety Monitoring Board (DSMB) review after 10 11 participants from each of the intervention arms completed assessments at study day 28. The 12

following criteria were established a priori for the DSMB to recommend discontinuation of 13 participant enrolment to either study arm: 14 -An absolute difference of ≥25% in the proportion of participants with an SAE 15 -An absolute difference of ≥25% in the proportion of participants with Grade 3 and 4 AEs 16 -The geometric mean ratio of anti-SARS-CoV-2 antibody between either intervention 17 group falls below 0.60. 18

Based on data from our ongoing COVID-19 vaccine immune-monitoring observational 20 prospective study (SCOPE), the mean level of SARS-CoV-2 anti-spike immunoglobulins by the 21 sVNT was 84% (standard deviation 15%) at 28 days after the second dose. 7 We expect 22

immunogenicity will be boosted back to the same level after the third booster dose in the control 23

Assuming an immunogenicity level of 84% in the control arm and a non-inferiority margin 1 of -10%, a sample size of 87 subjects per arm is needed to conclude non-inferiority of the 2 intervention arm against the control arm with 80% power. The sample size is calculated at a 3 one-sided 2.5% significance level and accounts for an attrition rate of 15%. 4

Serum samples were tested with a newly developed multiplex-sVNT assay using the Luminex 6 platform. 8 Briefly, AviTag-biotinylated receptor binding domain (RBD) proteins from wild-type 7 SARS-CoV-2 and five VOCs (Alpha, Beta, Gamma, Delta, Omicron) were coated on a MagPlex 8

Avidin microsphere (Luminex) at 5ug/1 million beads. RBD-coated microspheres (600 9 beads/antigen) were pre-incubated with serum at a final concentration of 1:20 or greater for 15 10 min at 37°C with 250 rpm agitation. After 15 min incubation, 50uL of phycoerythrin (PE)-11 conjugated hACE2 (GenScript 2ug/mL) were added to the well and incubated for 15 min at 37°C 12 with agitation, followed by two PBS-1% BSA washes. The final readings were acquired using 13 the MAGPIX system. 14 Serological results were obtained using the Elecsys® (Roche, Basel, Switzerland) Anti-SARS-15

CoV-2 chemiluminescent immunoassays following manufacturer instructions [anti-nucleocapsid 16 (anti-N) and anti-spike protein receptor binding domain (anti-S)]. Antibody titres in U/ml from the 17 Elecsys® anti-S assay are equivalent to the WHO standard Binding Antibody Units (BAU)/ml, 18 with no conversion required. 9 19

The Omicron variant (B.1.1.529/BA.1) isolate M21021166 was originally isolated by Prof. Gavin 21 Screaton, University of Oxford, UK, and then obtained from Prof. Wendy Barclay, Imperial 22

College London, London UK through the Genotype to Phenotype National Virology Consortium 23 (G2P-UK). Sequencing confirmed it contained the variant defining mutations. 10 Viral stock of 24

the SARS-CoV-2 Omicron isolate was generated in Vero/hSLAM cells with Dulbecco's minimal 1 essential medium (DMEM) (Sigma) containing 4% fetal bovine serum (FBS) (Sigma), 2 0.05 mg/ml gentamicin (Merck), and 0.4 mg/ml geneticin (G418; Thermo Fisher) and harvested 3 72 h post-inoculation. Virus stocks were aliquoted and stored at −80 °C as previously 4 described. 11 5

PRNTs were performed using African green monkey kidney C1008 (Vero E6) cells (Public 6

Health England, PHE). Sera were heat-inactivated at 56 °C for 1 h and stored at −20 °C until 7 use. DMEM containing 2% FBS and 0.05 mg/mL gentamicin was used for serial twofold 8 dilutions of patient plasma samples. SARS-CoV-2 at 800 PFU/mL was added to an equal 9 volume of diluted plasma and incubated at 37 °C for 1 h. The virus-plasma dilution was 10 inoculated onto Vero E6 cells in duplicate and incubated at 37 °C for 1 h. They were then 11 overlaid with agarose as in standard plaque assays. Cells were incubated for 72 h at 37 °C and 12 5% CO2 before being fixed with 10% formalin and stained with crystal violet solution (Sigma-13 Aldrich). Plaque reduction neutralisation test (PRNT) 90/80/50 was determined by the highest 14 dilution with a 90/80/50% reduction in plaques compared to the control. 15

Demographic and baseline characteristics were summarized by vaccine and age groups. For 17 comparison of vaccine reactions, categorical data was compared using Fisher's exact test or 18

Chi-square as appropriate. Anti-spike antibody titers were log 10 -transformed for all statistical 19 analysis, and compared using student's t-test. A multiple regression model of pre-vaccination 20 antibody titers was constructed, which included age (<60; ≥60 years), sex and time since 21 vaccination (in days) with the log 10 -transformed antibody titer as the dependent variable. 22

Omicron was conducted by Mann-Whitney U. No adjustments were made for multiple testing. 24

Written informed consent was obtained from all study participants (Domain Specific Review 4

Board ref no: 2021/00821). The study was registered with ClinicalTrials.gov (NCT05142319). All 5 data sharing requests should be addressed to the corresponding authors. 6

Results 7

Among 100 participants who received two primary doses of BNT162b2, 51 were randomized to 9 receive the homologous mRNA booster BNT162b2 (control group; BBB) and 49 to the 10 heterologous mRNA booster mRNA-1273 (intervention group; BBM) ( Figure 1 ). One participant 11 from each group withdrew from the study, resulting in an analysis sample size of 50 and 48 for 12 BBB and BBM groups, respectively. Baseline demographic characteristics of the participants 13 who received BBB or BBM in the younger (<60 years) or older (≥60 years) age groups are 14 shown in Table 1 . 15

No COVID-19 infections were recorded during the 28-day study period. All participants were 16 negative for anti-N antibody at baseline, Day 7 and Day 28. 17

The number of participants with solicited local and systemic adverse reactions (ARs) were 19 similar between the BBB and BBM groups (Supplementary Table 1 and Supplementary Figure  20 1). The most common local AR was injection site pain, with 89% and 87% of participants who 21 received BBB or BBM respectively experiencing pain at the injection site within 72 hours of a 22

booster dose. The most common systemic AR was fatigue/tiredness (BBB 70% and BBM 67%), 23 followed by muscle pain (BBB 61% and BBM 56%). 24

older age group where fever and weakness occurred more frequently in the BBM (35%) than 2 BBB (5%) group. 3 35 unsolicited adverse events (AEs) were reported by 25 participants, 12 in BBB and 13 in 4 BBM. No serious AEs were reported in the 28 days after vaccination in either age group. 5

Level of SARS-CoV-2 anti-S antibodies and neutralizing antibodies against the wild-type SARS-7

CoV-2 and VOCs were measured in serum samples collected before the booster dose (day -14 8

to Day 0) and at Days 7 and 28 after the booster dose. Before the booster dose and across all 9 participants, mean anti-S antibody titer in all participants was 555 IU/mL (95% CI 484 to 635 10 IU/mL), and median sVNT level 48.0% (inter-quartile range [IQR] 36.5 to 59.3%) and similar 11 between intervention groups. On multiple regression, baseline anti-S titers were significantly 12 lower with older age (p=0.0188) and among men (p=0.0051), but not with time since primary 13 vaccination series. 14 After the booster dose, anti-S titer across both intervention groups increased by 35-to 49-fold at 15

Day 7 to a mean of 23,158 IU/mL (95% CI 19,539 to 27,454 IU/mL), with only a modest further 16 increase by Day 28 (25,651 IU/mL (95% CI 22,444 to 29,322 IU/mL). Comparing study groups, 17 antibody titers were higher at both Day 7 (1.4-fold, p=0.0496) and Day 28 (1.3-fold, p=0.0339) in 18 the mRNA-1273 booster group compared with BNT162b2 ( Figure 2 ). This finding was 19 consistent when comparing neutralization levels against wild-type, Omicron and most of the 20 other variants (Figure 3) . 21

At pre-planned sub-group analysis, the anti-S antibody titers between BBB and BBM in the 22 younger age group were not significantly different at Days 7 and 28 post-booster, whereas older 23 participants who received BBM resulted in a significantly higher induction of anti-spike antibody 24 A C C E P T E D M A N U S C R I P T levels than those who received BBB. Mean anti-S titer was significantly higher with BBM than 1 BBB by 2.1-fold (p=0.0078) at Day 7 and 1.6-fold (p=0.0184) at Day 28. 2

The same trend was observed in inhibition level measured by sVNT against the wild-type 3 SARS-CoV-2 and VOCs. Older BBM participants had higher levels of neutralizing antibodies 4 against SARS-CoV-2 and all known VOCs, including Omicron ( Supplementary Table 2-4) . The 5 median wild-type SARS-CoV-2 sVNT inhibition level was modestly different at Day 28 (BBB 6 98.8% (IQR 95.3 to 99.0%) vs BBM 99.3% (IQR98.7 to 99.5%)) likely due to saturation, 7 although this achieved statistical significance (p=0.003). Table 5) . 20

The Omicron variant of SARS-CoV-2 has opened a new chapter in the COVID-19 pandemic 12 22 due to its high transmissibility and large number of mutations in the RBD region of the spike 23 protein 13 , which may explain its partial or complete resistance to antibody neutralization in fully 24 homologous and heterologous boosting, irrespective of primary vaccine series, to increase 4 neutralizing antibody titers. 14,15 In Singapore, a recent study of data from the Delta variant 5 outbreak found heterologous boosting to be associated with a lower incidence rate of SARS-6

CoV-2 infection than homologous boosting in adults 60 years and older. 16 However, the 7 comparative effect of different booster vaccine regimens on the serum neutralizing activity 8 against Omicron and other VOCs remains unknown. 9

This interim analysis describes the safety and immunogenicity of a homologous (BNT162b2, 10 BBB) or heterologous (mRNA-1272, BBM) mRNA booster dose in fully vaccinated adults 11 against clinically important VOCs such as Omicron. The adverse reactions after single booster 12 injections with BNT162b2 or mRNA-1273 were comparable between BBB and BBM groups, and 13 similar to those observed after the BNT162b2 primary series, which commonly include pain at 14 the site of injection, lethargy and muscle pain. 15

Six months after the primary vaccine series, mean neutralizing antibody titers against the wild-16 type SARS-CoV-2 declined to 40-60% in all groups. Additional reduction of neutralizing activity 17 against VOCs compared with the wild-type SARS-CoV-2 is a common trend in all participants 18 that is not influenced by age. Declining neutralization against the wild-type SARS-CoV-2 and 19 low neutralizing activity against Omicron after complete BNT162b2 vaccination calls for an 20 effective booster vaccine regimen to increase immune responses and protection. In this interim 21 analysis, we demonstrate that a booster dose can effectively enhance serum neutralizing 22 activity against the wild-type SARS-CoV-2 and all known VOCs Alpha, Beta, Gamma, Delta and 23

Omicron as early as Day 7 post-booster. More importantly, we evaluated and compared the 24 choice of booster dose for different age groups. For the vulnerable older age group in particular, 25

a heterologous booster COVID-19 vaccine regimen induces a higher anti-spike antibody titer 1 and a stronger neutralizing antibody response against the highly infectious Omicron variant 2 (~20% higher neutralization) than a homologous booster regimen. 3

This analysis is limited to healthy individuals receiving the BNT162b2 primary vaccine series, 4 and a recent study has shown that immunogenicity may be affected by the order of vaccine 5 products, though apparently less so than the combination. 17,18 Currently, it is not clear to what 6 extent the higher antibody levels observed in older BBM participants are due to superiority of 7 mRNA-1273 versus BNT126b2 or an effect of heterologous boosting. The PRIBIVAC study is 8 ongoing and in later phases of the study will include individuals who received mRNA-1273 as 9 their primary vaccine series to address this question. In addition, it is not known whether these 10 higher antibody peaks after vaccination will persist for the long term. Study participants will 11 continue to be followed up at 6 months and 12 months after their booster vaccination to 12 measure the rate of waning. 13

A study of this size is not likely to be able to determine vaccine effectiveness against infection, 14 and the clinical impact of this antibody difference in older adults needs to be determined. 16 15

Further studies are underway to characterize cell-mediated immunity in this cohort which may 16 indicate effectiveness against severe infection. 17

This study was initiated initially with only 2 arms (the control arm BBB and intervention arm 18 BBM) as the availability of other vaccine formulations are subjected to rigorous regulatory 19 scrutiny before they can be used in Singapore. We present interim results from this study 20 obtained before reaching our initial planned sample size due to new inclusion of Covaxin as a 21 booster dose to the study platforms adaptive protocol. It is unlikely the study findings will change 22 with a larger sample size given the large difference in the Omicron-specific neutralizing levels 23 among older adults. Singapore has rapidly expanded its COVID-19 booster vaccination 24 campaign, and currently 65% of adults aged ≥ 60 have received a booster dose. 25

such as Omicron. 19 Clinical trials are currently ongoing, but even if successful these vaccines 2 are not expected to be available till late in 2022. Thus, there is an urgent need for an effective 3 standard booster vaccination regimen, particularly in vulnerable populations, to reduce the risk 4 of severe disease and the present data provide evidence that a heterologous booster 5 vaccination in older individuals induces a more robust neutralization against the immune-6

evasive Omicron variant. This information is of paramount importance to inform future COVID-7 19 booster programs (third dose in other countries or fourth dose in Singapore) for older 8 individuals to better protect them against SARS-CoV-2 infection and severe disease. Future 9 follow-up analyses can provide further insights into the durability of the neutralizing antibody 10 response of the different vaccine booster combinations, as well as the neutralizing ability 11 against new VOCs. 12

Although the Omicron variant exerts considerable humoral immune escape in BNT162b2 fully 14 vaccinated individuals, a booster dose with BNT162b2 or mRNA-1273 is capable of increasing 15 the serum neutralizing activity against Omicron by more than 50% by Day 7 post-booster. In 16 older individuals who received BNT162b2 as their primary vaccine's series, a heterologous 17 booster regimen with mRNA-1273 induced a higher anti-spike antibody titer and a stronger 18 neutralizing response against the Omicron variant than a homologous booster regimen. 19

Acknowledgements 21

We thank Jinyan Zhang and Wee Chee Yap for technical assistance, and the Data and Safety 22

Monitoring Board (Jenny Low, David Allen, Alex R Cook) for their review and guidance. We 

The funders had no role in the design and conduct of the study; collection, management, 4 analysis, and interpretation of the data; preparation, review or approval of the manuscript; and 5 decision to submit the manuscript for publication. 6

Young reports personal fees from Astra-Zeneca, Gilead, Roche, Sanofi and Novacyte outside 8 the submitted work and payment or honoraria for lectures, presentations, speakers bureaus, 9 manuscript writing or educational events from Astra-Zeneca, Gilead, Roche, Sanofi, all paid to 10 institution. Tan, Wang and Chia report the following issued patent: United States Patent; Patent Participants in the older age group (≥60 years old) who received a heterologous COVID-19 5 vaccine booster (BBM) have significantly higher anti-SARS-CoV-2 IgG antibodies than those 6 who received a homologous mRNA booster (BBB) at day 7 and 28 post-vaccination. Data 7 analyzed using Student's t-test to compare the log 10 anti-S titer. Box represents 25 th and 75 th 8 percentile, line is median, with whiskers denoting extremes. Abbreviations: BBB, BNT162b2-9

BNT162b2-BNT162b2; BBM, BNT162b2-BNT162b2-mRNA-1273. *, p < 0.05; **, p < 0.01. 10 Figure 3 . Level of neutralizing antibodies against SARS-CoV-2 and variants of concern in 11 participants (a) below 60 years old and (b) 60 years old and above, and (c) summary data 12 for Omicron. Level of %inhibition was determined using a multiplex surrogate virus 13 neutralization test as previously described. 8 Data was analyzed using Mann-Whitney U test. 14 Red dotted line indicates inhibition of 30% (nominal 'seronegative' threshold). Data presented in 15 box plot and the line in the box indicates median. Abbreviations: BBB, BNT162b2-BNT162b2-16

BNT162b2; BBM, BNT162b2-BNT162b2-mRNA-1273. **, p < 0.01; ***, p < 0.001. 17 to vaccination (day 0) and at day 28 after the booster vaccination were screened for neutralizing 20 activity against Omicron variant of SARS-CoV-2. Plasma neutralizing activity comparison 21 between participants who received the homologous (BBB) and heterologous (BBM) mRNA 22 booster vaccine in the younger (<60 years, n=28) or older (≥60 years, n=12) age groups. Box 23 represents 25th and 75th percentile, line is median, with whiskers denoting extremes. 

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern

mRNA-based COVID-19 vaccine boosters 5 induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022. 6 3. WHO. 10 Vaccines Granted Emergency Use Listing (EUL) by WHO

Considerable escape of SARS-CoV-2 Omicron to antibody 9 neutralization

Plasma Neutralization of the SARS-CoV-2 Omicron 11 Variant

Omicron-B.1.1.529 leads to widespread escape from 13 neutralizing antibody responses

Durable T cell responses contrast with faster antibody 15 waning in BNT162b2-vaccinated elderly at 6 month. Nature Portfolio

Immunized SARS-CoV-1 Survivors

Anti-Spike Protein Assays to Determine SARS-19

Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays

Reduced neutralisation of SARS-CoV-2 omicron 22 B.1.1.529 variant by post-immunisation serum

Sequence analysis of SARS-CoV-2 in nasopharyngeal 24 samples from patients with COVID-19 illustrates population variation and diverse phenotypes, 25 placing the in vitro growth properties of B.1.1.7 and B.1.351 lineage viruses in context

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

Genomic perspectives on the emerging SARS-CoV-2 omicron variant

Homologous and Heterologous Covid-19 Booster 32 Vaccinations

Heterologous versus homologous COVID-19 34 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil 35 (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Association of Homologous and Heterologous Vaccine 38

Boosters With COVID-19 Incidence and Severity in Singapore

Safety and immunogenicity of heterologous versus 40 homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine 41 (Com-COV): a single-blind, randomised, non-inferiority trial

Emerging evidence on heterologous COVID-19 vaccine 43 schedules-To mix or not to mix?

Omicron is supercharging the COVID vaccine booster debate